[203Pb]VMT-α-NET

DRUG2 trials

Conditions

Bronchial Neuroendocrine TumorGastroenteropancreatic Neuroendocrine TumorNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Tumor MetastaticNeuroendocrine Tumors UnresectableParagangliomaPheochromocytoma

Early Phase 1

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Active, not recruitingNCT05111509

Yusuf MendaNeuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2

Start: 2022-08-22End: 2026-06-30Target: 20Updated: 2025-07-14

Phase 1

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

RecruitingNCT05636618

Perspective TherapeuticsBronchial Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumor Metastatic +3

Start: 2023-09-27End: 2029-12-26Target: 260Updated: 2025-11-24

Journal of Clinical Oncology2026-01-10

Abstract C095: [212Pb]VMT-a-NET for somatostatin receptor subtype 2 (SSTR2)-expressing tumors: safety and preliminary efficacy results in patients with advanced neuroendocrine tumors (NETs)

Molecular Cancer Therapeutics2025-10-22

[ <sup>212</sup> Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants.

Journal of Clinical Oncology2025-05-282 citations

Interim safety and efficacy data of [ <sup>212</sup> Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs).

Journal of Clinical Oncology2025-01-272 citations

[203Pb]VMT-α-NET

Sponsors

Conditions

Early Phase 1

Phase 1

Related Papers